BioNTech (NASDAQ:BNTX) Stock Falls 5.5% – Here’s Why

BioNTech SE Sponsored ADR (NASDAQ:BNTX)’s share price fell 5.5% during mid-day trading on Tuesday. The stock traded as low as $91.04 and last traded at $90.5320. Approximately 507,358 shares were traded during mid-day trading, a decline of 53% from the average session volume of 1,086,653 shares. The stock had previously closed at $95.84.

More BioNTech News

Here are the key news stories impacting BioNTech this week:

• Positive Sentiment: Canaccord Genuity maintained a Buy rating while lowering its price target from $136 to $132, implying substantial upside from recent trading levels. Canaccord Genuity BioNTech price target report
• Positive Sentiment: BioNTech plans to continue the AHEAD-MERIT trial, and Citi indicated that forthcoming overall-survival data could preserve a meaningful development path for BNT113 despite the initial efficacy miss. Citi analysis of BioNTech BNT113 trial
• Neutral Sentiment: Evercore ISI described the progression-free-survival miss as unsurprising, while BioNTech’s decision to continue the study keeps the program alive pending additional data. Evercore ISI analysis of BioNTech cancer vaccine trial
• Negative Sentiment: BNT113 failed to meet the primary progression-free-survival endpoint in the Phase 2/3 AHEAD-MERIT trial for metastatic HPV16-positive head-and-neck cancer. The result weakens confidence in BioNTech’s oncology strategy and triggered a sharp selloff. BioNTech BNT113 AHEAD-MERIT trial update
• Negative Sentiment: BMO tied the BNT113 failure to wider concerns about mRNA cancer-vaccine development and reaffirmed its Hold rating. Investors are now questioning whether the setback reflects a broader pipeline problem rather than an isolated trial outcome. BMO analysis of BioNTech BNT113 setback
• Negative Sentiment: SueWallSt announced a pending investigation into whether BioNTech’s statements about its mRNA oncology programs accurately represented the risks and prospects, adding potential legal and reputational pressure. SueWallSt BioNTech investigation notice

Wall Street Analysts Forecast Growth

Several equities research analysts recently commented on the stock. Wall Street Zen lowered shares of BioNTech from a “hold” rating to a “sell” rating in a research note on Saturday, August 8th. UBS Group reaffirmed a “buy” rating on shares of BioNTech in a research note on Wednesday, September 16th. Canaccord Genuity Group lowered their target price on shares of BioNTech from $136.00 to $132.00 and set a “buy” rating for the company in a report on Wednesday. Weiss Ratings reiterated a “sell (d-)” rating on shares of BioNTech in a report on Friday, October 2nd. Finally, BMO Capital Markets cut BioNTech from an “outperform” rating to a “market perform” rating and dropped their price target for the stock from $128.00 to $105.00 in a research report on Tuesday, September 8th. One equities research analyst has rated the stock with a Strong Buy rating, twelve have assigned a Buy rating, six have given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, BioNTech presently has an average rating of “Moderate Buy” and a consensus target price of $125.44.

BioNTech Price Performance

The firm has a fifty day moving average price of $99.12 and a two-hundred day moving average price of $95.30. The company has a quick ratio of 7.80, a current ratio of 7.85 and a debt-to-equity ratio of 0.01. The stock has a market capitalization of $22.42 billion, a P/E ratio of -11.32 and a beta of 1.25.

BioNTech (NASDAQ:BNTX) last announced its quarterly earnings data on Tuesday, August 4th. The company reported ($2.53) EPS for the quarter, missing the consensus estimate of ($2.40) by ($0.13). The firm had revenue of $122.31 million for the quarter, compared to analysts’ expectations of $180.18 million. BioNTech had a negative net margin of 63.54% and a negative return on equity of 6.86%. The business’s revenue for the quarter was down 59.5% compared to the same quarter last year. During the same period last year, the company posted ($1.60) earnings per share. On average, analysts expect that BioNTech SE Sponsored ADR will post -6.62 EPS for the current year.

Insider Activity at BioNTech

In related news, CEO Ugur Sahin sold 36,209 shares of the business’s stock in a transaction that occurred on Friday, October 9th. The shares were sold at an average price of $95.37, for a total value of $3,453,252.33. Following the completion of the transaction, the chief executive officer directly owned 36,209 shares in the company, valued at $3,453,252.33. The trade was a 50.00% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 807,209 shares of company stock worth $79,246,837 in the last 90 days. Corporate insiders own 19.20% of the company’s stock.

Institutional Trading of BioNTech

A number of institutional investors and hedge funds have recently modified their holdings of BNTX. Flossbach Von Storch SE bought a new stake in shares of BioNTech in the second quarter worth approximately $207,142,000. Bank of America Corp DE lifted its position in BioNTech by 22.6% during the first quarter. Bank of America Corp DE now owns 903,029 shares of the company’s stock valued at $80,261,000 after purchasing an additional 166,432 shares during the period. First Trust Advisors LP lifted its position in BioNTech by 116.0% during the first quarter. First Trust Advisors LP now owns 839,991 shares of the company’s stock valued at $74,658,000 after purchasing an additional 451,124 shares during the period. Assenagon Asset Management S.A. bought a new position in BioNTech during the second quarter valued at approximately $39,385,000. Finally, SEB Asset Management AB purchased a new stake in BioNTech in the first quarter worth approximately $17,804,000. Institutional investors own 15.52% of the company’s stock.

About BioNTech

BioNTech SE is a biotechnology company headquartered in Mainz, Germany, focused on developing therapies and vaccines for cancer and other serious diseases. The company’s research platform includes messenger RNA (mRNA), individualized cancer vaccines, immune-modulating therapies, cell therapies, and protein-based therapeutics.

BioNTech is best known for developing the Comirnaty COVID-19 vaccine in collaboration with Pfizer. Comirnaty uses mRNA technology to help stimulate an immune response against COVID-19 and has been distributed in markets around the world.